Abstral REMS Assessment To Look At Impact On Patient Access, Health Care System
Executive Summary
The extensive REMS assessment for ProStrakan's Abstral details the data collection burden sponsors face as they institute restricted distribution programs and FDA asks more questions about the burden placed on the health care system as well as the effects on patient access to medications.
You may also be interested in...
Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls
FDA's decision to create a class Risk Evaluation and Mitigation Strategy for all transmucosal fentanyl products indicates that the agency could take a similar strategy with the extended-release opioids.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.